We argue that in order to extrapolate the results of in vitro and in vivo animal works to human participants, one has to study NIBS effects on key components of AD pathology such as extra- and intracellular ion concentration changes, transendothelial resistance, and the proteins, primarily, Aβ and tau. Here, MAPT is linked to Alzheimer disease.